SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research
Most experimental oncology therapies fail during clinical development despite years of preclinical testing rationalizing their use. This begs the question of whether the current preclinical models used for evaluating oncology therapies adequately capture patient heterogeneity and response to therapy...
Main Authors: | Anthony Lima, Danilo Maddalo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.667189/full |
Similar Items
-
Editorial: Zebrafish as a model for human congenital disorders
by: Megha Kumar, et al.
Published: (2023-06-01) -
Detection of Campylobacter jejuni diversity by clustered regularly interspaced short palindromic repeats (CRISPR) from an animal farm
by: Hung‐Yueh Yeh, et al.
Published: (2021-11-01) -
CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
by: Sadegh Shojaei Baghini, et al.
Published: (2022-05-01) -
Clustered regularly interspaced short palindromic repeats-Cas9 gene therapy: The top 50 most-cited papers
by: Jude Howaidi, et al.
Published: (2019-01-01) -
Methods and Techniques to Facilitate the Development of Clostridium novyi NT as an Effective, Therapeutic Oncolytic Bacteria
by: Kaitlin M. Dailey, et al.
Published: (2021-03-01)